Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life sciences sectors.

Supporting its portfolio companies with a team of 27 at offices in London, Menlo Park, and Boston, Abingworth has invested in 142 life science companies, completed 60 IPOs and 40 mergers and acquisitions.

Abingworth

Partner

Chairman

Managing Partner

Investor

Chairman and Managing Partner

Executive Partner

Partner, Marketing and Talent

Principal

Partner and General Counsel

Investment Manager

Partner and CFO

Personalis raised $20000000 on 2011-08-15 in Series A

Personalis combines expertise both in the technology of sequencing and in interpretation, with an extensive history of peer-reviewed publication and commercial success. Broad adoption of medical genome interpretation will require accuracy befitting regulatory approval, both invariant detection and interpretation.

 The company was founded in 2011 and is based in Menlo Park, California.

Personalis

VirionHealth raised $17243071 on 2017-10-12 in Series A

VirionHealth Limited, a biotechnology company, develops novel therapeutics and biological therapeutics for respiratory viral infections and antiviral. The company also focuses on prevention and treatment of influenza and respiratory syncytial viruses. VirionHealth Limited was founded in 2015 and is based in Coventry, United Kingdom.

VirionHealth Limited

Oxagen raised $44240218 on 2000-12-21 in Venture Round

Oxagen Limited, a biopharmaceutical company, develops and commercializes anti-inflammatory medicines to treat asthma and other chronic allergic conditions. The company offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhinoconjunctivitis. Its drug programs target the CRTH2 receptor that initiates and maintains allergic conditions. The company develops a pipeline of small molecule drugs. It serves customers in the United Kingdom, Russia, CIS countries, and internationally. Oxagen Limited was incorporated in 1996 and is based in London, United Kingdom.

Oxagen

Chiasma raised $70000000 on 2015-02-27 in Series E

Chiasma (Israel) ltd., is a biopharmaceutical company which develops oral drugs based on transient permeability enhancer system. The company offers oral octreotide acetate for the treatment of acromegaly. Its pipeline products include novel drugs which addresses unmet needs for well-defined markets. The company focuses primarily on orphan indications. The company was founded in 2001 and is based in Ness Ziona, Israel. Chiasma (Israel) ltd. operates as a subsidiary of Chiasma, Inc.

Chiasma

Devgen raised $24675331 on 1999-10-01 in Series B

Devgen

ParAllele Bioscience raised $6000000 on 2005-04-14 in Convertible Note

Angel Dough Ventures is a startup accelerator that identifies new business ideas as well as develops and launches new products and services into the market. It also reviews customer feedback and analyzes metrics to transform and improve its businesses.

Angel Dough Ventures was founded by Andrew Hazen and is headquartered in Hicksville, New York.

ParAllele Bioscience

Hydra Biosciences raised $22000000 on 2009-01-16 in Series D

Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs.

Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs.

Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.

Hydra Biosciences

PrimeraDx (Primera Biosystems) raised $21000000 on 2008-01-09 in Series B

PrimeraDx, Inc. offers multiplexed infectious disease assays. It provides Scalable Target Amplification Routine technology, which is a method for simultaneous quantitative measurement of multiple target nucleic acids. The company also offers ViraQuant, a multiplexed assay providing quantitative and simultaneous measurement of viruses; and FungiQuant Yeast and FungiQuant Mold, which are fungal panels for mycology testing. Its products are used in miRNA, DNA methylation, quantitative genotyping, gene expression, and viral load measurement applications. PrimeraDx, Inc. was founded in 2004 and is based in Mansfield, Massachusetts.

PrimeraDx (Primera Biosystems)

Adaptate Biotherapeutics raised $18189221 on 2021-04-19 in Series A

Adaptate is a biotherapeutics company that develops antibodies to modulate gamma delta T cells in situ. The company was founded in 2019 by Adrian Hayday and is headquartered in London.

Adaptate Biotherapeutics

Labcyte raised $21000000 on 2005-07-25 in Series C

Lab­cyte Inc. is a lab­o­ra­tory instru­men­ta­tion com­pany with a novel approach to dis­pens­ing small vol­umes of liq­uids for life sci­ences appli­ca­tions. The company's acoustic dis­pens­ing tech­nol­ogy uses a focused beam of acoustic energy to eject nanoliter-​​scale droplets of fluid from one plate to another, with high accu­racy at low vol­umes and reduced con­sum­ables costs.  In addi­tion to DBL Investors, investors include Alloy Ven­tures, Abing­worth, New Leaf Ven­ture Part­ners, and Cross Atlantic Partners.

Labcyte was founded in 2000 and is based in San Jose, California, United States.

Labcyte

Magellan Diagnostics raised $50000000 on 2006-11-29 in Private Equity Round

Magellan Diagnostics, Inc., a medical device company, develops and manufactures point-of-care systems, clinical laboratory instruments, and analytical laboratory services focused on lead testing. Its products include LeadCare II, a blood lead testing system; LeadCare Ultra, which provides blood lead results for laboratories; and LeadCare Plus, a solution for laboratories with smaller volumes for performing lead testing in house. The company also provides various analytical services, such as lead and heavy metal exposure, monitoring exposure in employees, and testing. It offers solutions for clinicians, public health providers, managed care organizations, and families and communities. Magellan Diagnostics, Inc. was formerly known as Magellan Biosciences, Inc. The company was founded in 2004 and is headquartered in North Billerica, Massachusetts. Magellan Diagnostics, Inc. operates as a subsidiary of Magellan Biosciences, Inc.

Magellan Diagnostics

Sientra raised $65000000 on 2012-03-28 in Series C

Sientra, Inc., a medical device company, develops and markets products focusing on the plastic surgery and aesthetics market. The company is based in Santa Barbara, California.  Sientra is committed to providing plastic surgeons with intuitive, elegant solutions—as reflected in its innovative round and shaped product lines.  It offers breast implants, breast tissue expanders, silicone scar treatment, and additional tissue expanders.

Sientra, Inc.

Effector Therapeutics raised $40000000 on 2015-12-23 in Series B

eFFECTOR Therapeutics is an early stage company focused on the discovery and development of new small molecule cancer therapeutics. eFFECTOR is developing translation regulators to selectively block disregulated translation impacting tumor growth and survival. The company has selected control of mRNA translation as a key point of theerapeutic intervention, providing potency and selectivity while inhibiting growth of cancer cells. eFFECTOR's novel approach provides a real opportunity to bring innovative new medicines to patients in need.

Effector Therapeutics

Virion Biotherapeutics raised $17000000 on 2017-10-01 in Series A

Virion’s mission is a developer of biological antivirals creates to offer improved therapeutics for respiratory viral infections. The company's antivirals focus on prevention and treatment of influenza and respiratory syncytial virus (RSV), enabling doctors to get a broad-spectrum therapy for respiratory viral infections, potentially simplifying and accelerating treatment by removing the need for differential diagnosis.

Virion Biotherapeutics

Adiana raised $23000000 on 2005-08-25 in Series D

Adiana, Inc. engages in the development and testing of transcervical sterilization system for permanent birth control. It develops Complete TCS, which consists of a radiofrequency generator, delivery catheter, and implantable matrix. The company was founded in 1997 and is based in Redwood City, California. As of March 16, 2007, Adiana, Inc. is a subsidiary of CYTYC Corp.

Adiana

Q32 Bio raised $60000000 on 2020-10-29 in Series B

Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.

Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.

Q32 Bio

Jasper Therapeutics raised an undisclosed amount on 2020-01-25 in Series A

Jasper Therapeutics, Inc., a biotechnology company, develops therapeutic agents for hematopoietic stem cell transplants and gene therapies. It offers JSP191, a humanized monoclonal antibody in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow, which binds to human CD117, a receptor for stem cell factor that is expressed on the surface of hematopoietic stem and progenitor cells. Jasper Therapeutics, Inc. was incorporated in 2018 and is based in Menlo Park, California.

Jasper Therapeutics

Supernus Pharmaceuticals raised $17500000 on 2006-01-12 in Series A

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The company’s extensive expertise in product development has been built over the past 20 years: initially as a stand alone development organization, then as a U.S. subsidiary of Shire plc and, upon its acquisition of substantially all the assets of Shire Laboratories Inc. in late 2005, as Supernus Pharmaceuticals. The company is developing several product candidates in neurology and psychiatry to address large market opportunities in epilepsy, ADHD and depression. In addition to its two ADHD product candidates, Supernus is developing two late stage epilepsy product candidates, SPN-538 (extended release topiramate), and Epliga® (extended release oxcarbazepine).

Supernus Pharmaceuticals, Inc.

NeoRX Corporation (Poniard Pharmaceuticals) raised $65000000 on 2006-02-01 in Post-IPO Equity

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer.

NeoRX Corporation (Poniard Pharmaceuticals)

Protein Mechanics raised an undisclosed amount on 2001-03-01 in Series A

Protein Mechanic is developing cross-disciplinary computational techniques to accelerate drug-discovery and design. Their novel methods allow physically accurate modeling of biomolecular systems to take place at unprecedented speeds. They intend to use these methods to make in silico biology an everyday tool for medical researchers.

Located in a vibrant downtown setting in the heart of Silicon Valley, they are 15 minutes from Stanford University, with easy access to freeways and mass transit. Their work style is informal, collaborative, and intellectually stimulating. They are backed by experienced, well-funded, long-term focused biotech venture capitalists and a world-class group of scientific advisors committed to their success.

Protein Mechanics

Valeritas raised $50000000 on 2008-09-10 in Series A

On June 30, 2020, Valeritas Holdings, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.

Valeritas Holdings, Inc.

Direct Conversion raised $20963075 on 2002-07-01 in Series B

Direct Conversion  provides detectors into imaging systems that are used across the globe

Direct Conversion AB (publ)

Scorpion Therapeutics raised $108000000 on 2020-10-26 in Series A

Scorpion Therapeutics, Inc., a biotechnology company, develops next-generation precision oncology technologies for the treatment of cancer. The company develops precision oncology drugs in three areas, including therapies against known oncogenes; agents for known but currently undruggable cancer targets; and drugs for new targets. Scorpion Therapeutics, Inc. was founded in 2020 and is based in Boston, Massachusetts.

Scorpion Therapeutics, Inc.

Gynesonics raised $21000000 on 2013-02-20 in Series D

Gynesonics, Inc. designs and develops minimally invasive solutions for symptomatic uterine fibroids in women. The company offers Sonography-Guided Transcervical Fibroid Ablation (Sonata) System(The Sonata System) for the transcervical treatment of symptomatic uterine fibroids under intrauterine sonography guidance serving customers in the European Union. Gynesonics, Inc. was founded in 2005 and is based in Redwood City, California with an additional location in Beuningen, the Netherlands.

Gynesonics

Clinical Designs raised an undisclosed amount on 2000-03-01 in Venture Round

Clinical Designs is a maker of devices for drug delivery via the respiratory system.

Clinical Designs

Clovis Oncology raised $145000000 on 2009-05-21 in Venture Round

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Their development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.

Clovis Oncology, Inc.

Zogenix raised $18000000 on 2008-01-09 in Series B

At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. 

We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.

Zogenix

NIDO raised an undisclosed amount on 2020-12-24 in Venture Round

Nido Surgical, Inc. develops medical instrument for heart surgery. The company was founded in 2014 and is based in Needham, Massachusetts.

Nido Surgical, Inc.

CRISPR Therapeutics raised $35000000 on 2015-04-29 in Series A

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing.

CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

CRISPR Therapeutics AG

Ascend Gene & Cell Therapies raised $65900000 on 2023-05-09 in Series A

Ascend

Broncus Technologies raised an undisclosed amount on 2008-07-24 in Debt Financing

Broncus Technologies is a medical technology company focused on developing minimally-invasive medical devices for emphysema and other lung diseases. Broncus is investigating the Exhale emphysema product line to perform our patented treatment method called Airway Bypass. Airway Bypass could be the first minimally-invasive procedure for the treatment of homogeneous, or diffuse, emphysema, which constitutes the majority of the emphysema patient population.

Broncus is currently enrolling patients worldwide in our pivotal EASE Trial investigating a treatment of severe homogeneous emphysema.

Broncus is located in Mountain View, CA (San Francisco Bay area).

Broncus International is located in Nyon, Switzerland.

BRONCUS MEDICAL INC.

Pixium Vision raised $20279368 on 2013-11-25 in Series A

Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system to treat blindness caused by degeneration of photoreceptor cells in the retina. The company has collaboration agreements with Stanford University in California, Institut de la Vision, Moorfields Eye Hospital, Institute of Ocular Microsurgery, University Hospital, and UPMC. Pixium Vision SA was founded in 2011 and is based in Paris, France.

Pixium Vision SA

GTx raised $48500000 on 2017-09-26 in Post-IPO Equity

GTx, Inc. is a company of pioneering and driven individuals who are delivering better medicines with new science through established pathways.

Entelos raised $25000000 on 2001-09-06 in Series C

Entelos is the leading provider of predictive biosimulation for drug discovery and development. We provide advanced biosimulation capabilities that make discovery more efficient and increase clinical success.

For over 15 years, we have enabled R&D organizations to predict better paths to success by simulating systems biology. Our solutions include mechanism-based, mathematical models; virtual patients and populations; biosimulation software; and biosimulation expertise.

Entelos

Verona Pharma raised $65627780 on 2016-06-20 in Post-IPO Equity

Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis (hay fever), chronic obstructive pulmonary disease (COPD) and cough.

Verona Pharma

Portola Pharmaceuticals raised $21000000 on 2003-12-10 in Series A

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis, and other hematologic disorders and inflammation in Europe and the United States. Its lead product Andexxa, an antidote for the treatment of rivaroxaban and apixaban under the Ondexxya Brand. The company offers Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients for an acute medical illness. It also develops cerdulatinib, an investigational oral, dual spleen tyrosine kinase, and janus kinases inhibitor for the treatment of hematologic cancers; and Syk inhibitors. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Daiichi Sankyo, Inc.; Bayer Pharma, AG; Takeda, Ora, Inc.; Astellas Pharma Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 2003 and is headquartered in South San Francisco, California. As of July 1, 2020, Portola Pharmaceuticals, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc.

MD On-Line raised $12000000 on 2011-05-18 in Venture Round

MD On-Line Inc. is a leading provider of electronic data interchange (EDI) solutions that facilitate the critical connection between doctors and payers. Its offerings enable electronic data capture and entry, and claim and transactional data submission to payers. Co-branded and endorsed by more than 30 major insurers and increasing its presence in providers' offices of all sizes, MD On-Line is transacting the business of healthcare, helping to make the healthcare system significantly more cost-effective by eradicating inefficiencies. In addition to claims processing, MD On-Line offers real-time services for eligibility verification, referrals, claim status inquiries, and electronic remittance advice (ERAs). Its "all-payer" EDI solutions encompass a network of more than 2,000 payer organizations and are used by more than 45,000 healthcare providers nationwide.

MD On-Line

Kesios Therapeutics raised $28401362 on 2015-12-02 in Series A

Kesios Therapeutics Limited develops small molecule drugs for haematological malignancies, such as multiple myeloma The NF-κB Pathway and Novel Oncology Target (GADD45β/MKK7), Research and Development pipeline and related indications. The company was incorporated in 2012 and is based in Cambridge, United Kingdom.

Kesios Therapeutics

Q32 Bio raised an undisclosed amount on 2020-10-29 in Series B

inMediata raised an undisclosed amount on 2006-01-01 in Venture Round

inMediata, formerly known as Secure EDI is a technology company dedicated to increasing the efficiency and reducing the cost of healthcare. It creates seamless connections among providers and payers for sharing information and providing secure, on-line processing of claim and payment transactions.

The company provides electronic solutions for efficiency in dental and health care offices through seamless interfaces between payers and providers. Its solutions include real-time adjudication of claims, electronic funds transfer, converting paper to electronic along with a full range of electronic transactions.

inMediata

Avillion raised an undisclosed amount on 2013-01-28 in Venture Round

Avillion LLP, a drug development company, focuses on clinical development and approval of late stage pharmaceutical products and candidates. It offers opportunities to partner late phase therapeutic projects for approval, and to accelerate their availability to the market. The company also provides global clinical trial, global regulatory, and CRO management services. It serves pharmaceutical and biotechnology companies. The company was incorporated in 2012 and is based in London, United Kingdom.

Avillion LLP

Jasper Therapeutics raised $14100000 on 2020-01-25 in Series A

Soleno Therapeutics raised $16500000 on 2018-12-19 in Post-IPO Equity

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Soleno Therapeutics

Avedro raised $43000000 on 2013-03-05 in Series D

Medical device and pharmaceutical company advancing the science and technology of corneal cross-linking

Avedro

Vaxcyte raised $85000000 on 2018-06-07 in Series C

Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).

SutroVax

Broncus Technologies raised $29500000 on 2006-09-01 in Series F

Dicerna Pharmaceuticals raised $60000000 on 2013-07-31 in Series C

Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others.

The company was founded in 2007 and is headquartered in Lexington, Massachusetts.

Dicerna Pharmaceuticals

Alnylam Pharmaceuticals raised $24600000 on 2003-07-07 in Venture Round

Alnylam (Nasdaq: ALNY) is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

Alnylam Pharmaceuticals

Dynogen Pharmaceuticals raised $50000000 on 2004-04-20 in Series B

Dynogen is a privately held, neuroscience-based pharmaceutical company focused on genitourinary (GU) and gastrointestinal (GI) disorders. The company is utilizing its knowledge of the nexus between neurology and GU/GI disorders, as well as its predictive in vitro and in vivo pharmacology platforms to rapidly build a pipeline of development programs. Today, Dynogen has two ongoing development programs, one for overactive bladder (OAB) and another for irritable bowel syndrome (IBS). The company will advance its OAB program into Phase IIa trials and enter the clinic with its IBS program later this year.

Dynogen Pharmaceuticals

Hydra Biosciences raised $9300000 on 2002-07-26 in Series A

Intelligent Medical Implants Ltd raised $19084018 on 2006-10-30 in Series B

IMI Intelligent Medical Implants develops and markets intelligent retinal implant systems for degenerative retinal disorders. The company offers The Intelligent Retinal Implant System, an adaptive visual prosthesis that bridges and replaces the defective information processing function of the real retina in patients with retinal degeneration.

IMI Intelligent Medical Implants was founded in 2002 and is based in Zug, Switzerland.

Intelligent Medical Implants Ltd

Guava Technologies raised $7000000 on 2005-11-29 in Venture Round

Guava Technologies, Inc. develops, designs, and manufactures biotechnology and medical devices. Its products include HIV/AIDS monitoring, viacount cell counting and viability assay, antibody quantification assay, apoptosis assay suite, cell cycle assay, cytotoxicity assay, cell proliferation assay, and benchtop cell analysis systems. Guava Technologies also offers flow cytometry systems for cell biology research, drug discovery and development, and HIV/AIDS monitoring. It serves life science research, drug discovery and development, cell biology research, core flow cytometry, and clinical diagnostics markets. The company's products are used in cell counting/viability, antibody quantification, cell cycle and proliferation, cytotoxicity, and apoptosis applications. Guava Technologies, Inc. was founded in 1998 and is headquartered in Hayward, California. As of February 20, 2009, Guava Technologies, Inc. operates as a subsidiary of Millipore Corp.

Guava Technologies

Vaxcyte raised $22000000 on 2015-07-23 in Series A

Intellikine raised $51000000 on 2009-07-22 in Series B

Intellikine works in the discovery and development of novel, small molecule therapies targeting the PI3K/Akt/mTOR pathway. 

Intellikine is committed to building an exceptional team and a powerful discovery platform that rapidly generates small molecule kinase inhibitor drug candidates that will become the next generation of medical breakthroughs.

Intellikine

Valeritas raised $150000000 on 2011-09-12 in Series C

Guava Technologies raised an undisclosed amount on 2005-11-04 in Series E

Oxagen raised $59800000 on 2005-05-23 in Series B

CRISPR Therapeutics raised $25000000 on 2015-04-30 in Series B

Sunesis Pharmaceuticals raised $6000000 on 2002-12-20 in Series C

Sunesis is an emerging biopharmaceutical company creating new medicines to improve the lives of people with cancer. They are building a pipeline of drugs that selectively block critical mechanisms required for tumor growth and survival. The fight against cancer is an enormous mission that requires an integrated approach fueled by a commitment to innovation.

Sunesis Pharmaceuticals

Labcyte raised $5300000 on 2013-01-08 in Series D

NuCana BioMed raised $80000000 on 2020-10-13 in Post-IPO Equity

NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines.

NuCana BioMed

Attenua raised $35000000 on 2018-05-01 in Series A

Attenua, Inc. is a virtual biotech company formed to develop therapies for debilitating conditions neglected by Big Pharma's shift to specialty Pharma and biologics.  They believe small molecule Blockbuster drugs that would benefit millions are still to be discovered.

They have assembled a team of leading scientists and ex-Big Pharma advisors with many years of drug development expertise. Their team has previous work experience at Merck, GSK, AstraZeneca, and Genentech.

Attenua

Spruce Biosciences raised $88000000 on 2020-02-20 in Series B

Spruce Biosciences is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. The company is driven by its mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal. They are committed to transforming the quality of life for patients who have been underserved by scientific innovation.

Spruce Biosciences, Inc.

Syntaxin raised $29000000 on 2010-11-11 in Series C

Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

Syntaxin

Algeta raised $35000000 on 2009-02-18 in Post-IPO Equity

Algeta ASA, an oncology company, focused on developing targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. Its lead product includes radium-223 dichloride, which completed Phase III clinical trial to treat castration-resistant prostate cancer with bone metastases. The company is also developing alpha-emitter thorium-227 that is in the preclinical phase linked to tumor-targeting molecules to form targeted thorium conjugates. It has an agreement with Bayer Pharma AG for the development and commercialization of radium-223 worldwide. The company was formerly known as Anticancer Therapeutic Inventions AS and changed its name to Algeta ASA in 2003. Algeta ASA was founded in 1997 and is headquartered in Oslo, Norway.

Algeta

Chroma Therapeutics raised $53000000 on 2006-04-03 in Series C

Chroma Therapeutics Ltd. develops novel small molecule drugs based on chromatin biology and novel cell accumulation approaches for targeted cancer and inflammation treatments. Its products include Tosedostat, an oral aminopeptidase inhibitor; CHR-3996, an optimized histone deacetylase inhibitor for the treatment of cancer; and CHR-2845, a targeted solution for haemotological malignancies. The company was founded in 2000 and is based in Abingdon, United Kingdom.

Chroma Therapeutics Ltd.

Nouscom raised $48767347 on 2017-11-06 in Series B

Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy.

The NousCom team is lead by experienced enterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies.

Nouscom

Q32 Bio raised $46000000 on 2020-05-27 in Series A

Avila Therapeutics raised $22500000 on 2010-07-07 in Venture Round

Avila Therapeutics, Inc. designs and develops covalent drugs for viral infections, cancers, and autoimmune diseases. It offers AVL-181, a small molecule hepatitis C virus protease inhibitor.

 Avila Therapeutics, Inc. has a strategic alliance with Sanofi-Aventis. The company was incorporated in 2006 and is based in Waltham, Massachusetts. 

As of March 7, 2012, Avila Therapeutics, Inc. operates as a subsidiary of Celgene Corporation.

Avila Therapeutics

Oxagen raised $26700000 on 2009-11-24 in Series C

GammaDelta Therapeutics raised an undisclosed amount on 2016-09-16 in Seed Round

GammaDelta Therapeutics is developing the potential of gamma delta (γδ) cells to create improved immunotherapy of cancer and other serious diseases. The company plans to exploit unique properties of tissue resident γδ T cells for effective immunotherapy.

GammaDelta Therapeutics

Sunesis Pharmaceuticals raised $8000000 on 1998-12-01 in Series A

Personalis raised $33000000 on 2015-01-13 in Series C